(Reuters)-Biogen Inc (NASDAQ :) said Thursday that approval of a drug for Alzheimer’s disease is based on extensive data to calm concerns about drug efficacy while reporting initial sales of $ 2 million for the drug. Said that.
The U.S. Food and Drug Administration’s decision to approve aducanumab has been criticized by doctors and hospitals, despite a committee of outside experts recommending opposition, and does not prescribe or prescribe treatment very much. There is also an opinion that it is slow.
The company’s stock rose 1.3% to $ 327.44 in early trading, boosted by Biogen’s higher earnings forecast for the full year.
“We welcome a formal review of the FDA-Biogen interaction towards approval of aducanumab. A better understanding of the facts is good for everyone involved,” R & D director Alfred Sandrock said in an open letter. That’s it. ” Addressed to the Alzheimer’s disease community.
According to Refinitiv’s IBES data, the company’s revenue for the quarter was $ 2 million, compared to analysts’ average estimate of $ 3.23 million.
Revenues from aducanumab are modest this year and are expected to increase thereafter.
Biogen currently expects total sales of $ 10.65 billion to $ 10.85 billion this year, compared to $ 10.45 billion to $ 10.75 billion. The company generated $ 448.5 million ($ 2.99 per share) in the second quarter, which ended June 30, down from $ 1.54 billion ($ 9.59 per share) in the year-ago quarter.
Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Please be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.
Biogen defends Alzheimer’s disease drug approval, reporting $ 2 million in initial Reuters sales
Source link Biogen defends Alzheimer’s disease drug approval, reporting $ 2 million in initial Reuters sales